Aurinia Pharmaceuticals Inc. to Post Q4 2024 Earnings of $0.12 Per Share, Leerink Partnrs Forecasts (NASDAQ:AUPH)

Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) (TSE:AUP) – Research analysts at Leerink Partnrs lifted their Q4 2024 earnings estimates for Aurinia Pharmaceuticals in a research report issued on Thursday, May 2nd. Leerink Partnrs analyst J. Schwartz now forecasts that the biotechnology company will post earnings of $0.12 per share for the quarter, up from their prior forecast of $0.09. The consensus estimate for Aurinia Pharmaceuticals’ current full-year earnings is ($0.06) per share. Leerink Partnrs also issued estimates for Aurinia Pharmaceuticals’ FY2025 earnings at $0.23 EPS.

Aurinia Pharmaceuticals (NASDAQ:AUPH) (TSE:AUP) last announced its quarterly earnings data on Thursday, February 15th. The biotechnology company reported ($0.19) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.16) by ($0.03). The firm had revenue of $45.10 million during the quarter, compared to analysts’ expectations of $45.00 million. Aurinia Pharmaceuticals had a negative return on equity of 14.79% and a negative net margin of 32.69%. The company’s revenue for the quarter was up 58.8% compared to the same quarter last year. During the same quarter in the previous year, the business earned ($0.18) earnings per share.

A number of other analysts also recently commented on AUPH. StockNews.com upgraded Aurinia Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Friday. Jefferies Financial Group dropped their price objective on shares of Aurinia Pharmaceuticals from $9.50 to $9.00 and set a “hold” rating on the stock in a research note on Friday, February 16th. Royal Bank of Canada dropped their price target on shares of Aurinia Pharmaceuticals from $13.00 to $8.00 and set an “outperform” rating on the stock in a research report on Friday, February 16th. Cantor Fitzgerald dropped their target price on Aurinia Pharmaceuticals from $12.00 to $10.00 and set an “overweight” rating on the stock in a research report on Friday, February 23rd. Finally, HC Wainwright reiterated a “buy” rating and set a $13.00 price target on shares of Aurinia Pharmaceuticals in a research report on Friday, March 1st. One investment analyst has rated the stock with a hold rating and four have given a buy rating to the company’s stock. According to MarketBeat.com, Aurinia Pharmaceuticals currently has an average rating of “Moderate Buy” and a consensus price target of $10.00.

Aurinia Pharmaceuticals Trading Down 1.4 %

NASDAQ AUPH opened at $5.10 on Monday. The company has a fifty day moving average of $5.20 and a 200 day moving average of $7.10. The company has a market capitalization of $729.40 million, a PE ratio of -11.86 and a beta of 1.36. The company has a debt-to-equity ratio of 0.20, a current ratio of 5.50 and a quick ratio of 4.99. Aurinia Pharmaceuticals has a 1 year low of $4.71 and a 1 year high of $12.43.

Institutional Inflows and Outflows

Hedge funds have recently modified their holdings of the stock. China Universal Asset Management Co. Ltd. increased its stake in Aurinia Pharmaceuticals by 95.9% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 3,673 shares of the biotechnology company’s stock worth $29,000 after buying an additional 1,798 shares in the last quarter. Vermillion & White Wealth Management Group LLC acquired a new position in Aurinia Pharmaceuticals in the 4th quarter valued at $30,000. Tidemark LLC purchased a new position in Aurinia Pharmaceuticals in the 4th quarter valued at $39,000. DekaBank Deutsche Girozentrale purchased a new stake in shares of Aurinia Pharmaceuticals during the third quarter worth $65,000. Finally, Eagle Asset Management Inc. acquired a new stake in shares of Aurinia Pharmaceuticals in the fourth quarter valued at about $92,000. Institutional investors and hedge funds own 36.83% of the company’s stock.

Aurinia Pharmaceuticals Company Profile

Aurinia Pharmaceuticals Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States. It offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co, Ltd.